Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH
SL Hauser, DM Dawson, JR Lehrich, MF Beal, SV Kevy, RD Propper, JA Mills, and HL Weiner
Fifty-eight patients with severe, progressive multiple sclerosis were prospectively randomized to one of three treatments: 20 received intravenous ACTH, 20 received high-dose intravenous cyclophosphamide plus ACTH, and 18 were placed on a regimen consisting of plasma exchange, low-dose oral cyclophosphamide, and ACTH. The three groups were similar in age, sex, duration and type of disease, and degree of disability. Before treatment and six months and one year after treatment, a disability-status score, ambulation index, and functional-status score were determined, and a quantitative neurologic examination was performed. In the ACTH group, the number of patients stabilized or improved was 8 of 20 at six months and 4 of 20 at one year; in the cyclophosphamide-ACTH group, 18 of 20 at six months and 16 of 20 at one year; and in the plasma exchange group, 11 of 18 at six months and 9 of 18 at one year. High-dose cyclophosphamide plus ACTH was most effective in halting progression of the disease at both 6 and 12 months (at 12 months, cyclophosphamide-ACTH vs. ACTH, P = 0.0004; cyclophosphamide-ACTH vs. plasma exchange, P = 0.087). Thus, progressive multiple sclerosis may be stabilized by short-term, intensive immunosuppression with cyclophosphamide plus ACTH.
This article has been cited by other articles:
Simeoni, M., Auquier, P., Fernandez, O., Flachenecker, P., Stecchi, S., Constantinescu, C., Idiman, E., Boyko, A., Beiske, A., Vollmer, T., Triantafyllou, N., O'Connor, P., Barak, Y., Biermann, L., Cristiano, E., Atweh, S., Patrick, D., Robitail, S., Ammoury, N., Beresniak, A., Pelletier, J. on behalf
(2008). Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult Scler
14: 219-230
[Abstract]
Pohl, D., Waubant, E., Banwell, B., Chabas, D., Chitnis, T., Weinstock-Guttman, B., Tenembaum, S., for the International Pediatric MS Study Group,
(2007). Treatment of pediatric multiple sclerosis and variants. Neurology
68: S54-S65
[Abstract][Full Text]
Creange, A, Serre, I, Levasseur, M, Audry, D, Nineb, A, Boerio, D, Moreau, T, Maison, P, Reseau SINDEFI-SEP,
(2007). Walking capacities in multiple sclerosis measured by global positioning system odometer. Mult Scler
13: 220-223
[Abstract]
Terzi, N., Orlikowski, D., Aegerter, P., Lejaille, M., Ruquet, M., Zalcman, G., Fermanian, C., Raphael, J.-C., Lofaso, F.
(2007). Breathing-Swallowing Interaction in Neuromuscular Patients: A Physiological Evaluation. Am. J. Respir. Crit. Care Med.
175: 269-276
[Abstract][Full Text]
Julian, L, Merluzzi, N M, Mohr, D C
(2007). The relationship among depression, subjective cognitive impairment, and neuropsychological performance in multiple sclerosis. Mult Scler
13: 81-86
[Abstract]
Julian, L. J., Mohr, D. C.
(2006). Cognitive Predictors of Response to Treatment for Depression in Multiple Sclerosis. J. Neuropsychiatry Clin. Neurosi.
18: 356-363
[Abstract][Full Text]
Nocentini, U, Pasqualetti, P, Bonavita, S, Buccafusca, M, De Caro, M F, Farina, D, Girlanda, P, Le Pira, F, Lugaresi, A, Quattrone, A, Reggio, A, Salemi, G, Savettieri, G, Tedeschi, G, Trojano, M, Valentino, P, Caltagirone, C
(2006). Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Mult Scler
12: 77-87
[Abstract]
Smith, D R, Weinstock-Guttman, B, Cohen, J A, Wei, X, Gutmann, C, Bakshi, R, Olek, M, Stone, L, Greenberg, S, Stuart, D, Orav, J, Stuart, W, Weiner, H
(2005). A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler
11: 573-582
[Abstract]
Frohman, E. M., Stuve, O., Havrdova, E., Corboy, J., Achiron, A., Zivadinov, R., Sorensen, P. S., Phillips, J. T., Weinshenker, B., Hawker, K., Hartung, H.-P., Steinman, L., Zamvil, S., Cree, B. A. C., Hauser, S., Weiner, H., Racke, M. K., Filippi, M.
(2005). Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations. Arch Neurol
62: 1519-1530
[Abstract][Full Text]
Fisk, J D, Brown, M G, Sketris, I S, Metz, L M, Murray, T J, Stadnyk, K J
(2005). A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J. Neurol. Neurosurg. Psychiatry
76: 58-63
[Abstract][Full Text]
Jeffery, D. R., Herndon, R.
(2004). Review of mitoxantrone in the treatment of multiple sclerosis. Neurology
63: S19-S24
[Abstract][Full Text]
Rizvi, S. A., Bashir, K.
(2004). Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology
63: S47-S54
[Abstract][Full Text]
Pearson, O.R., Busse, M.E., van Deursen, R.W.M., Wiles, C.M.
(2004). Quantification of walking mobility in neurological disorders. QJM
97: 463-475
[Full Text]
Visser, L H, Beekman, R, Tijssen, C C, Uitdehaag, B M., Lee, M L, Movig, K L., Lenderink, A W
(2004). A randomized, double-blind, placebo-controlled pilot study of IV immune globulins in combination with IV methylprednisolone in the treatment of relapses in patients with MS. Mult Scler
10: 89-91
[Abstract]
Portaccio, E, Zipoli, V, Siracusa, G, Piacentini, S, Sorbi, S, Amato, M P
(2003). Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort. Mult Scler
9: 446-450
[Abstract]
Mohr, D. C., Hart, S. L., Goldberg, A.
(2003). Effects of Treatment for Depression on Fatigue in Multiple Sclerosis. Psychosom. Med.
65: 542-547
[Abstract][Full Text]
Bowen, J. D, Maravilla, K., Margolin, S. B
(2003). Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis. Mult Scler
9: 280-283
[Abstract]
Beatty, W. W, Orbelo, D. M, Sorocco, K. H, Ross, E. D
(2003). Comprehension of affective prosody in multiple sclerosis. Mult Scler
9: 148-153
[Abstract]
McKeown, L P, Porter-Armstrong, A P, Baxter, G D
(2003). The needs and experiences of caregivers of individuals with multiple sclerosis: a systematic review. Clin Rehabil
17: 234-248
[Abstract]
Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., Thompson, A. J.
(2003). Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology
60: 31-36
[Abstract][Full Text]
Galetta, S. L., Markowitz, C., Lee, A. G.
(2002). Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis: A Systematic Review. Arch Intern Med
162: 2161-2169
[Abstract][Full Text]
Aupperle, R L, Beatty, W W, deNAP Shelton, F, Gontkovsky, S T
(2002). Three screening batteries to detect cognitive impairment in multiple sclerosis. Mult Scler
8: 382-389
[Abstract]
Beatty, W W
(2002). Fluency in multiple sclerosis: which measure is best?. Mult Scler
8: 261-264
[Abstract]
Weiner, H L, Cohen, J A
(2002). Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler
8: 142-154
[Abstract]
Lincoln, N B, Dent, A, Harding, J, Weyman, N, Nicholl, C, Blumhardt, L D, Playford, E D
(2002). Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry
72: 93-98
[Abstract][Full Text]
Rossier, P., Wade, D. T
(2002). The Guy's Neurological Disability Scale in patients with multiple sclerosis: a clinical evaluation of its reliability and validity. Clin Rehabil
16: 75-95
[Abstract]
Cramer, S C, Fray, E, Tievsky, A, Parker, R A, Riskind, P N, Stein, M C, Wedeen, V, Rosen, B R
(2001). Changes in motor cortex activation after recovery from spinal cord inflammation. Mult Scler
7: 364-370
[Abstract]
Noseworthy, J. H., O'Brien, P. C., Petterson, T. M., Weis, J., Stevens, L., Peterson, W. K., Sneve, D., Cross, S. A., Leavitt, J. A., Auger, R. G., Weinshenker, B. G., Dodick, D. W., Wingerchuk, D. M., Rodriguez, M.
(2001). A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology
56: 1514-1522
[Abstract][Full Text]
Khan, O. A, Zvartau-Hind, M., Caon, C., Din, M. U, Cochran, M., Lisak, D., Tselis, A. C, Kamholz, J. A, Garbern, J. Y, Lisak, R. P
(2001). Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler
7: 185-188
[Abstract]
Bowen, J., Gibbons, L., Gianas, A., Kraft, G. H
(2001). Self-administered Expanded Disability Status Scale with functional system scores correlates well with a physician-administered test. Mult Scler
7: 201-206
[Abstract]
Bryant, J, Clegg, A, Milne, R
(2001). Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?. J. Neurol. Neurosurg. Psychiatry
70: 574-579
[Abstract][Full Text]
Schultheis, M. T., Garay, E., DeLuca, J.
(2001). The influence of cognitive impairment on driving performance in multiple sclerosis. Neurology
56: 1089-1094
[Abstract][Full Text]
Pfeiffer, G, Wicklein, E M, Ratusinski, T, Schmitt, L, Kunze, K
(2001). Disability and quality of life in Charcot-Marie-Tooth disease type 1. J. Neurol. Neurosurg. Psychiatry
70: 548-550
[Abstract][Full Text]
Noseworthy, J. H., O'Brien, P. C., Weinshenker, B. G., Weis, J. A., Petterson, T. M., Erickson, B. J., Windebank, A. J., Whisnant, J. P., Stolp-Smith, K. A., Harper, C. M. Jr., Low, P. A., Romme, L. J., Johnson, M., An, K.-N., Rodriguez, M.
(2000). IV immunoglobulin does not reverse established weakness in MS: A double-blind, placebo-controlled trial. Neurology
55: 1135-1143
[Abstract][Full Text]
Krajewski, K. M., Lewis, R. A., Fuerst, D. R., Turansky, C., Hinderer, S. R., Garbern, J., Kamholz, J., Shy, M. E.
(2000). Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain
123: 1516-1527
[Abstract][Full Text]
Golomb, J, Wisoff, J, Miller, D C, Boksay, I, Kluger, A, Weiner, H, Salton, J, Graves, W
(2000). Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J. Neurol. Neurosurg. Psychiatry
68: 778-781
[Abstract][Full Text]
Hohol, M. J, Olek, M. J, Orav, E J., Stazzone, L., Hafler, D. A, Khoury, S. J, Dawson, D. M, Weiner, H. L
(1999). Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease. Mult Scler
5: 403-409
[Abstract]
Miki, Y., Grossman, R. I., Udupa, J. K., Wei, L., Polansky, M., Mannon, L. J., Kolson, D. L.
(1999). Relapsing-Remitting Multiple Sclerosis: Longitudinal Analysis of MR Images-Lack of Correlation between Changes in T2 Lesion Volume and Clinical Findings. Radiology
213: 395-399
[Abstract][Full Text]
Liu, C., Blumhardt, L. D
(1999). Randomised, double blind, placebo controlled study of interferon beta -1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves. J. Neurol. Neurosurg. Psychiatry
67: 451-456
[Abstract][Full Text]
Hohol, M J, Orav, E J, Weiner, H L
(1999). Disease steps in multiple sclerosis: a longitudinal study comparing Disease Steps and EDSS to evaluate disease progression. Mult Scler
5: 349-354
[Abstract]
Puccioni-Sohler, M., Rios, M., Bianco, C., Zhu, S. W., Oliveira, C., Novis, S. A. P., Pombo-de-Oliveira, M. S.
(1999). An inverse correlation of HTLV-I viral load in CSF and intrathecal synthesis of HTLV-I antibodies in TSP/HAM. Neurology
53: 1335-1335
[Abstract][Full Text]
Clark, W. F., Rock, G. A., Buskard, N., Shumak, K. H., LeBlond, P., Anderson, D., Sutton, D. M., for the Canadian Apheresis Group*,
(1999). Therapeutic Plasma Exchange: An Update from the Canadian Apheresis Group. ANN INTERN MED
131: 453-462
[Abstract][Full Text]
Amato, M. P., Ponziani, G.
(1999). Quantification of impairment in MS: discussion of the scales in use. Mult Scler
5: 216-219
[Abstract]
Sharrack, B., Hughes, R. A.
(1999). The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler
5: 223-233
[Abstract]
Schroder, M.
(1999). MUSIS 2.0-Multiple Sclerosis Information System: An easy-to-use-database to improve the care of patients with multiple sclerosis. Mult Scler
5: 299-301
Hadden, R. D. M., Sharrack, B., Bensa, S., Soudain, S. E., Hughes, R. A. C.
(1999). Randomized trial of interferon {beta}-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology
53: 57-57
[Abstract][Full Text]
Rostami, A M, Sater, R A, Bird, S J, Galetta, S, Farber, R E, Kamoun, M, Silberberg, D H, Grossman, R I, Pfohl, D
(1999). A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis. Mult Scler
5: 198-203
[Abstract]
Cutter, G. R., Baier, M. L., Rudick, R. A., Cookfair, D. L., Fischer, J. S., Petkau, J., Syndulko, K., Weinshenker, B. G., Antel, J. P., Confavreux, C., Ellison, G. W., Lublin, F., Miller, A. E., Rao, S. M., Reingold, S., Thompson, A., Willoughby, E.
(1999). Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain
122: 871-882
[Abstract][Full Text]
Goodin, D. S, Northern California MS Study Group,
(1999). Survey of multiple sclerosis in Northern California. Mult Scler
5: 78-88
[Abstract]
Liu, C., Edwards, S., Gong, Q., Roberts, N., Blumhardt, L. D
(1999). Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry
66: 323-330
[Abstract][Full Text]
Forlander, D. A, Bohannon, R. W
(1999). Rivermead Mobility Index: a brief review of research to date. Clin Rehabil
13: 97-100
[Abstract]
Sharrack, B., Hughes, R. A. C., Soudain, S., Dunn, G.
(1999). The psychometric properties of clinical rating scales used in multiple sclerosis. Brain
122: 141-159
[Abstract][Full Text]
Solari, A., Filippini, G., Gasco, P., Colla, L., Salmaggi, A., La Mantia, L., Farinotti, M., Eoli, M., Mendozzi, L.
(1999). Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology
52: 57-57
[Abstract][Full Text]
Schwartz, C. E., Vollmer, T., Lee, H.
(1999). Reliability and validity of two self-report measures of impairment and disability for MS. Neurology
52: 63-63
[Abstract][Full Text]
Burt, R. K., Traynor, A. E., Pope, R., Schroeder, J., Cohen, B., Karlin, K. H., Lobeck, L., Goolsby, C., Rowlings, P., Davis, F. A., Stefoski, D., Terry, C., Keever-Taylor, C., Rosen, S., Vesole, D., Fishman, M., Brush, M., Mujias, S., Villa, M., Burns, W. H.
(1998). Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation. Blood
92: 3505-3514
[Abstract][Full Text]
Paul, R. H, Beatty, W. W, Schneider, R., Blanco, C., Hames, K.
(1998). Impairments of attention in individuals with Multiple Sclerosis. Mult Scler
4: 433-439
[Abstract]
Beatty, W. W, Hames, K. A, Blanco, C. R, Williamson, S. J, Wilbanks, S. L, Olson, K. A
(1998). Correlates of coping style in patients with multiple sclerosis. Mult Scler
4: 440-443
[Abstract]
Goodin, D. S
(1998). A questionnaire to assess neurological impairment in multiple sclerosis. Mult Scler
4: 444-451
[Abstract]
Zalneraitis, E. L., Vonsattel, J.-P.
(1998). Case 26-1998- A 15-Year-Old Girl with Hemiparesis, Slurred Speech, and an Intracranial Lesion. NEJM
339: 542-549
[Full Text]
Liu, C., Po, A. L. W., Blumhardt, L. D
(1998). "Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry
64: 726-729
[Abstract][Full Text]
Khoury, S. J., Weiner, H. L.
(1998). Multiple Sclerosis: What Have We Learned From Magnetic Resonance Imaging Studies?. Arch Intern Med
158: 565-573
[Abstract][Full Text]
Rudick, R. A., Cohen, J. A., Weinstock-Guttman, B., Kinkel, R. P., Ransohoff, R. M.
(1997). Management of Multiple Sclerosis. NEJM
337: 1604-1611
[Full Text]
Gayou, A., Brochet, B., Dousset, V.
(1997). Transitional progressive multiple sclerosis: a clinical and imaging study. J. Neurol. Neurosurg. Psychiatry
63: 396-398
[Abstract][Full Text]
Vaney, C., Blaurock, H., Gattlen, B., Meisels, C.
(1996). Assessing mobility in multiple sclerosis using the Rivermead Mobility Index and gait speed. Clin Rehabil
10: 216-226
[Abstract]
Vollmer, T. L.
(1996). Multiple Sclerosis: New Approaches to Immunotherapy. Neuroscientist
2: 127-136
[Abstract]
Beatty, W. W., Blanco, C. R., Wilbanks, S. L., Paul, R. H., Hames, K. A.
(1995). Demographic, Clinical, and Cognitive Characteristics of Multiple Sclerosis Patients Who Continue to Work. Neurorehabil Neural Repair
9: 167-173
[Abstract]
Bever, C. T. JR, Anderson, P. A., Smith, G. V., Panitch, H. S., Johnson, K. P.
(1995). Isometric Measurement of Hamstrings and Quadriceps Strength in Multiple Sclerosis Patients: Sensitivity and Variability. Neurorehabil Neural Repair
9: 221-227
[Abstract]
Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M.-C., Rocchiccioli, F., Cartier, N., Jambaque, I., Jakobezak, C., Lemaitre, A., Boureau, F., Wolf, C., Bougneres, P.-F.
(1993). A Two-Year Trial of Oleic and Erucic Acids ("Lorenzo's Oil") as Treatment for Adrenomyeloneuropathy. NEJM
329: 745-752
[Abstract][Full Text]
O'Brien, M. T.
(1993). Multiple Sclerosis: The Role of Social Support and Disability. Clin Nurs Res
2: 67-85
[Abstract]
Mooney, C., Mushlin, A. I., Phelps, C. E.
(1990). Targeting Assessments of Magnetic Resonance Imaging in suspected Multiple sclerosis. Med Decis Making
10: 77-94
[Abstract]
